ReviewTherapeutic advances in urology
A narrative review of biparametric MRI (bpMRI) implementation on screening, detection, and the overall accuracy for prostate cancer.
Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Optimal MRI sequence for predicting extraprostatic extension in prostate cancer: comparison of LCC and MaxRADD measurements.Abdominal radiology (New York) · 2026Article
- PI-RADS 2.1 is valid for detecting prostate cancer in bpMRI in an Irish population.Irish journal of medical science · 2026Article
- Simplatab: An Automated Machine Learning Framework for Radiomics-Based Bi-Parametric MRI Detection of Clinically Significant Prostate Cancer.Bioengineering (Basel, Switzerland) · 2025Article
- Biparametric MRI-based radiomics for noninvastive discrimination of benign prostatic hyperplasia nodules (BPH) and prostate cancer nodules: a bio-centric retrospective cohort study.Scientific reports · 2025Article
- Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer.European urology open science · 2025Article
- Article
- The Diagnostic Value of bpMRI in Prostate Cancer: Benefits and Limitations Compared to mpMRI.Bioengineering (Basel, Switzerland) · 2024Article
- Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population.Abdominal radiology (New York) · 2024Article
- Article
- FastMRI Prostate: A public, biparametric MRI dataset to advance machine learning for prostate cancer imaging.Scientific data · 2024Article
- Prostate cancer screening in African American men: a review of the evidence.Journal of the National Cancer Institute · 2024Review
- Could Biparametric MRI Replace Multiparametric MRI in the Management of Prostate Cancer?Life (Basel, Switzerland) · 2023Review
- State-of-the-art Prostate Imaging.Sisli Etfal Hastanesi tip bulteni · 2023Review
- Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignancy in American men following skin cancer, with approximately one in eight men being diagnosed during their lifetime. Over the past several decades, the treatment of prostate cancer has evolved rapidly, so too has screening. Since the mid-2010s, magnetic resonance imaging (MRI)-guided biopsies or 'targeted biopsies' has been a rapidly growing topic of clinical research within the field of urologic oncology. The aim of this publication is to provide a review of biparametric MRI (bpMRI) utilization for the diagnosis of prostate cancer and a comparison to multiparametric MRI (mpMRI). Through single-centered studies and meta-analysis across all identified pertinent published literature, bpMRI is an effective tool for the screening and diagnosis of prostate cancer. When compared with the diagnostic accuracy of mpMRI, bpMRI identifies prostate cancer at comparable rates. In addition, when omitting dynamic contrast-enhanced (DCE) protocol to the MRI, patients incur reduced costs and shorter imaging time while providers can offer more tests to their patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.